Photo from academic.microsoft.com
In accordance with US Food and Drug Administration recommendations, tumor PD-L1 expression should be assessed in all patients with platinum-ineligible metastatic urothelial carcinoma (mUC), and patients with low PD-L1 expression… Click to show full abstract
In accordance with US Food and Drug Administration recommendations, tumor PD-L1 expression should be assessed in all patients with platinum-ineligible metastatic urothelial carcinoma (mUC), and patients with low PD-L1 expression should not receive single-agent immune checkpoint inhibition treatment. By contrast, PD-L1 should not be tested in metastatic renal cell carcinoma and platinum-refractory mUC.
Keywords:
advanced genitourinary;
genitourinary malignancies;
role testing;
urology;
testing advanced
Journal Title: European urology focus
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European urology focus
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!